Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003255
Status:
COMPLETED
Last Update Posted:
2016-07-12
First Post:
1999-11-01
Brief Title:
Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia
Sponsor:
Alliance for Clinical Trials in Oncology
Organization:
Alliance for Clinical Trials in Oncology
Study Overview
Official Title:
Phase II Study of Continuous Infusion Carboplatin and Topotecan in the Treamtment of Relapsed Acute Myelogenous Leukemia AML
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining more than one drug may kill more tumor cells
PURPOSE Phase II trial to study the effectiveness of combining carboplatin and topotecan in treating patients with relapsed acute myelogenous leukemia
PURPOSE Phase II trial to study the effectiveness of combining carboplatin and topotecan in treating patients with relapsed acute myelogenous leukemia
Detailed Description:
OBJECTIVES I Determine the efficacy of a 5-day continuous infusion of carboplatin and topotecan in patients with relapsed and refractory acute myelogenous leukemia AML II Assess the toxic effects of this treatment in these patients
OUTLINE Patients receive continuous intravenous infusions of topotecan and carboplatin for 5 days Treatment repeats every 3-4 weeks during induction two courses and every 6-10 weeks during consolidation No more than four courses of treatment are given Patients are followed every 6 months for 5 years
OUTLINE Patients receive continuous intravenous infusions of topotecan and carboplatin for 5 days Treatment repeats every 3-4 weeks during induction two courses and every 6-10 weeks during consolidation No more than four courses of treatment are given Patients are followed every 6 months for 5 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000066143 | REGISTRY | PDQ Physician Data Query | None |